Question 2: Should hypertonic saline be used in patients with cystic fibrosis who respond unsatisfactorily to recombinant deoxyribonuclease?

Archives of Disease in Childhood

Volumn 95, Issue 7, 2010, Pages 562-564

  Badurdeen, Shiraz ^a   Ross Russell, Robert ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DORNASE ALFA; SODIUM CHLORIDE;

ADJUVANT THERAPY; CASE REPORT; CHEST TIGHTNESS; CHILD; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LUNG FUNCTION; NEBULIZATION; NOTE; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; WHEEZING;

CHILD; CYSTIC FIBROSIS; DEOXYRIBONUCLEASES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; SALINE SOLUTION, HYPERTONIC;

EID: 77953736569     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2008.141226     Document Type: Note

References (12)

1. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
2. Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros 2002;1:35-7.
3. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-21.
4. Davies J, Trindade MT, Wallis C, et al. Retrospective review of the effects of rhDNase in children with cystic fibrosis. Pediatr Pulmonol 1997;23:243-8.
5. Suri R, Metcalfe C, Wallis C, et al. Predicting response to rhDNase and hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 2004;37:305-10.
6. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005;3:CD001506.
7. Eng PA, Morton J, Douglass JA, et al. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
8. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
9. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50.
10. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
11. Smith G. A patient's view of cystic fibrosis. J Adolesc Health Care 1986;7:134-8.
12. Bye PT, Elkins MR. Other mucoactive agents for cystic fibrosis. Paediatr Respir Rev 2007;8:30-9.